Clinical trial
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
NCT05800366 is registered in ClinicalTrials.gov with Jennifer Crombie, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
- Lead sponsor
- Jennifer Crombie, MD
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 6, 2023
- Completion date
- September 15, 2029
- Enrollment
- 41 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.